Original Article
A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease
Efectividad y seguridad en nuestro entorno del adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
Víctor Manuel Navas-Lópeza,b,
, Gemma Pujol-Muncunillc, Enrique Llerenac, María Navalón Rubiod, David Gil-Ortegad, Vicente Varea-Calderónc, Carlos Sierra Salinasa,b, Javier Martin-de-Carpic
a Sección de Gastroenterología y Nutrición Infantil, Hospital Materno Infantil, Málaga, Spain
b Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
c Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
d Unidad de Gastroenterología y Nutrición Pediátrica, Hospital Virgen de la Arrixaca, Murcia, Spain
Read
9549
Timeswas read the article
3380
Total PDF
6169
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 6 | 24 |
| 2025 5 | 105 | 30 | 135 |
| 2025 4 | 80 | 20 | 100 |
| 2025 3 | 87 | 24 | 111 |
| 2025 2 | 83 | 27 | 110 |
| 2025 1 | 77 | 29 | 106 |
| 2024 12 | 56 | 31 | 87 |
| 2024 11 | 86 | 54 | 140 |
| 2024 10 | 46 | 46 | 92 |
| 2024 9 | 56 | 33 | 89 |
| 2024 8 | 65 | 59 | 124 |
| 2024 7 | 47 | 36 | 83 |
| 2024 6 | 58 | 30 | 88 |
| 2024 5 | 56 | 33 | 89 |
| 2024 4 | 73 | 38 | 111 |
| 2024 3 | 63 | 34 | 97 |
| 2024 2 | 62 | 26 | 88 |
| 2024 1 | 52 | 25 | 77 |
| 2023 12 | 73 | 17 | 90 |
| 2023 11 | 60 | 20 | 80 |
| 2023 10 | 54 | 27 | 81 |
| 2023 9 | 31 | 23 | 54 |
| 2023 8 | 36 | 26 | 62 |
| 2023 7 | 70 | 26 | 96 |
| 2023 6 | 32 | 26 | 58 |
| 2023 5 | 66 | 33 | 99 |
| 2023 4 | 50 | 29 | 79 |
| 2023 3 | 68 | 23 | 91 |
| 2023 2 | 40 | 24 | 64 |
| 2023 1 | 34 | 31 | 65 |
| 2022 12 | 75 | 31 | 106 |
| 2022 11 | 88 | 55 | 143 |
| 2022 10 | 79 | 64 | 143 |
| 2022 9 | 42 | 46 | 88 |
| 2022 8 | 69 | 62 | 131 |
| 2022 7 | 65 | 57 | 122 |
| 2022 6 | 73 | 63 | 136 |
| 2022 5 | 84 | 43 | 127 |
| 2022 4 | 144 | 66 | 210 |
| 2022 3 | 174 | 72 | 246 |
| 2022 2 | 155 | 57 | 212 |
| 2022 1 | 136 | 57 | 193 |
| 2021 12 | 71 | 56 | 127 |
| 2021 11 | 91 | 59 | 150 |
| 2021 10 | 74 | 108 | 182 |
| 2021 9 | 45 | 48 | 93 |
| 2021 8 | 43 | 64 | 107 |
| 2021 7 | 41 | 48 | 89 |
| 2021 6 | 43 | 49 | 92 |
| 2021 5 | 82 | 60 | 142 |
| 2021 4 | 320 | 139 | 459 |
| 2021 3 | 81 | 75 | 156 |
| 2021 2 | 50 | 24 | 74 |
| 2021 1 | 43 | 32 | 75 |
| 2020 12 | 59 | 20 | 79 |
| 2020 11 | 48 | 27 | 75 |
| 2020 10 | 30 | 23 | 53 |
| 2020 9 | 42 | 27 | 69 |
| 2020 8 | 42 | 25 | 67 |
| 2020 7 | 50 | 24 | 74 |
| 2020 6 | 47 | 12 | 59 |
| 2020 5 | 89 | 35 | 124 |
| 2020 4 | 32 | 11 | 43 |
| 2020 3 | 99 | 40 | 139 |
| 2020 2 | 212 | 30 | 242 |
| 2020 1 | 114 | 17 | 131 |
| 2019 12 | 120 | 25 | 145 |
| 2019 11 | 46 | 15 | 61 |
| 2019 10 | 51 | 10 | 61 |
| 2019 9 | 37 | 22 | 59 |
| 2019 8 | 77 | 18 | 95 |
| 2019 7 | 46 | 40 | 86 |
| 2019 6 | 39 | 30 | 69 |
| 2019 5 | 63 | 20 | 83 |
| 2019 4 | 59 | 44 | 103 |
| 2019 3 | 56 | 26 | 82 |
| 2019 2 | 64 | 33 | 97 |
| 2019 1 | 86 | 32 | 118 |
| 2018 12 | 77 | 38 | 115 |
| 2018 11 | 154 | 33 | 187 |
| 2018 10 | 191 | 32 | 223 |
| 2018 9 | 79 | 26 | 105 |
| 2018 8 | 4 | 0 | 4 |
| 2018 7 | 6 | 0 | 6 |
| 2018 6 | 5 | 0 | 5 |
| 2018 5 | 14 | 0 | 14 |
| 2018 4 | 39 | 0 | 39 |
| 2018 3 | 40 | 0 | 40 |
| 2018 1 | 0 | 12 | 12 |
| 2017 12 | 0 | 19 | 19 |
| 2017 11 | 0 | 23 | 23 |
| 2017 10 | 0 | 23 | 23 |
| 2017 9 | 0 | 20 | 20 |
| 2017 8 | 0 | 18 | 18 |
| 2017 7 | 0 | 15 | 15 |
| 2017 6 | 0 | 31 | 31 |
| 2017 5 | 0 | 49 | 49 |
| 2017 4 | 0 | 114 | 114 |
Show all
